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Abstract The role of b-adrenoceptor antagonists (b-
blockers) in cardiovascular therapy has been subject to
diverse trends and changes over the decades. With the
advent of a wide variety of excellent drugs for the treat-
ment of antihypertension, b-blockers have been relegated
from the first-line treatment of essential hypertension.
However, they remain the drugs of first choice in recom-
mendations from the respective medical societies for heart
failure, coronary artery disease, and atrial fibrillation as
well as in hypertension complicated with heart failure,
angina pectoris, or prior myocardial infarction. When
indicated, cardioselective b-blockers should be prescribed
in patients with diabetes mellitus or chronic obstructive
pulmonary disease. We review the available evidence for
the use of b-blockers in clinical conditions in which rec-
ommendations can be made for everyday practice.
Key Points
b-Adrenoceptor antagonists (b-blockers) are
recommended for the first-line treatment of heart
failure, coronary artery disease, and atrial fibrillation
as well as of hypertension complicated with heart
failure, angina pectoris, or prior myocardial
infarction.
b-Blockers should not be withheld from patients with
diabetes mellitus or chronic obstructive pulmonary
disease, although cardioselective agents are
preferable.
1 Introduction
Agents that block the adrenergic b-receptors have been
used for decades in the treatment of cardiovascular disease
(CVD). The development of primary prevention and early-
detection strategies as well as the emergence of new and
effective therapeutic agents has seen the survival rates and
life expectancy of patients with CVD increase consider-
ably, with a consequent increase in the prevalence of these
conditions [1]. Patients who develop a chronic heart dis-
ease usually need lifelong treatment, and finding the opti-
mal personalized treatment for every patient is crucial.
According to new hypertension guidelines [2], b-
blockers have been forced into the second line of thera-
peutic recommendations for essential hypertension, behind
angiotensin-converting enzyme (ACE) inhibitors, angio-
tensin receptor blockers (ARBs), and calcium channel
blockers (CCBs). These recommendations were based on
meta-analyses reporting that b-blockers may be less
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favorable than some other drug classes for total mortality,
cardiovascular (CV) events, and stroke outcomes. How-
ever, most of the analyzed data came from studies using
atenolol and propranolol and may not apply to other agents
[2, 3].
Treatment choices for patients with CVD should be
based on the presence and magnitude of all risk factors and
comorbid conditions as well as on the individual charac-
teristics of the drugs in question (the primary characteris-
tics of commonly used b-blockers are presented in
Table 1). Compared with traditional b-blockers, newer
agents with b1 selectivity or vasodilating properties (such
as carvedilol or nebivolol) reduce central pulse pressure
and aortic stiffness more effectively than atenolol or
metoprolol and tend to have fewer metabolic side effects
[2].
We present the available evidence for the use of b-
blockers in relation to CVD. A comprehensive PubMed
search was performed to identify relevant articles for
discussion.
2 b-Blockers in Heart Failure
Heart failure (HF) is strongly correlated with hypertension:
75% of incident HF cases are preceded by elevated blood
pressure [4]. b-Blockers reduce heart rate and blood pres-
sure and have anti-arrhythmogenic and anti-ischemic
effects [5]. Besides directly blocking sympathetic activity
in the heart, they also inhibit ACE release from the jux-
taglomerular apparatus [6]. In patients with HF, the action
of b-blockers against the harmful effects of increased
adrenergic activity (resulting from myocardial dysfunction)
facilitates improvements in ventricular structure and
function [5]. Long-term use of b-blockers in patients with
HF has been shown to significantly improve hemodynamic
parameters; b-blockade results in increased left ventricular
stroke volume index and left ventricular ejection fraction
(EF), reduced cardiac index, and decreased pulmonary
artery and wedge pressure [7–11].
The use of a b-blocker along with an ACE inhibitor is
recommended by the European Society of Cardiology
Table 1 Characteristics of commonly used b-blockers


























? ? - - -
Atenolol Chronic stable angina;
following MI; cardiac
arrhythmia
50–100 6–7 Mainly renal ? - - - -
Bisoprolol HF with reduced EF 1.25–10 9–12 Renal 50%;
non-renal
50%
? - - - -
Carvedilol Mild to severe HF; chronic
stable angina; following
MI
3.125–100 6–10 Mainly non-
renal
- - ? ? ?
Metoprolol HF; chronic stable angina;
following MI;
tachyarrhythmia;
50–450 3–9 Mainly renal ? - - ? -
Nadolol Chronic stable angina;
tachyarrhythmia;
thyrotoxicosis
20–240 20–24 Mainly renal - - - - -




? ? - - ?
Propranolol Chronic stable angina;
following MI; cardiac
arrhythmias; thyrotoxicosis
10–320 3–6 10% renal;
90% non-
renal
- - - ? -
CVD cardiovascular disease, EF ejection fraction, HF heart failure, ISA intrinsic sympathomimetic activity, MI myocardial infarction
a All listed drugs are indicated for the treatment of hypertension
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(ESC) and American Heart Association (AHA) guidelines
for all patients with systolic HF with reduced EF to prevent
symptomatic HF, improve left ventricular remodeling, and
reduce the risk of hospitalization and premature death
(level I A evidence). Treatment should be started as soon as
possible after diagnosis. In coexisting atrial fibrillation
(AF), a b-blocker should be the first-line treatment to
control the ventricular rate (level I A evidence); in all
patients with a recent or remote history of myocardial
infarction (MI) or acute coronary syndrome (ACS) and
reduced EF, a b-blocker should be used to reduce mortality
(level I B evidence) [12, 13]. According to the ESC
guideline on peripheral artery disease, b-blockers are not
contraindicated in patients with lower extremity artery
disease (LEAD) and should be considered in concomitant
HF (level IIa B evidence) [14].
2.1 Heart Failure with Reduced Ejection Fraction
Recommendations for the use of b-blockers in HF with
reduced EF are mainly based on the outcomes of large
randomized placebo-controlled trials investigating biso-
prolol (CIBIS-II), carvedilol (COPERNICUS), metoprolol
(MERIT-HF), and nebivolol (SENIORS) (see Table 2 for
the full names of trials mentioned in this article) [12, 13].
These trials have shown the investigated b-blockers to
effectively reduce the risk of mortality and admission to
hospital (Table 3) [15, 16]. These results verified earlier
findings from randomized studies, meta-analyses of which
found that the reduction in mortality risk was[30% with
the use of b-blockers [9, 19, 20]. A recent network meta-
analysis of 21 randomized controlled trials (RCTs) further
confirmed approximately the same reduction in all-cause
mortality risk. The effect sizes were consistent when
comparing trials with shorter and longer ([12 months)
follow-up durations. b-Blockers also significantly reduced
deaths from CVD as well as sudden deaths. Head-to-head
comparisons of individual b-blockers did not show sig-
nificant differences in the evaluated outcomes, suggesting a
strong class effect [7].
There may be individual differences between different
b-blockers with regard to clinical outcomes in HF with
reduced EF, as suggested by some comparative studies.
The COMET investigators found a significant difference in
all-cause mortality rate with carvedilol versus bisoprolol
[hazard ratio (HR) 0.83; p = 0.0017) [21]. In a retrospec-
tive cohort, carvedilol and bisoprolol but not metoprolol
significantly reduced the risk of death and hospitalization
Table 2 Acronyms and full names of trials mentioned in this article
Short name Full name
AF-CHF Atrial Fibrillation and Congestive Heart Failure
AFFIRM The Atrial Fibrillation Follow-up Investigation of Rhythm Management
BEST Beta-Blocker Evaluation in Survival Trial
BHAT Beta Blocker Heart Attack Trial
BIP Bezafibrate Intervention Study
CAPRICORN Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction
CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance
CIBIS-II Cardiac Insufficiency Bisoprolol Study
COMET Carvedilol Or Metoprolol European Trial
COMMIT Clopidogrel and Metoprolol in Myocardial Infarction Trial
COPERNICUS Carvedilol Prospective Randomized Cumulative Survival
ISIS-1 First International Study of Infarct Survival
J-DHF Japanese Diastolic Heart Failure Study
MERIT-HF Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure
MIAMI Metoprolol in acute myocardial infarction
MOCHA Multicenter Oral Carvedilol Heart Failure Assessment
MUSTT Multicenter Unsustained Tachycardia Trial
PRECISE Percutaneous Robotically Enhanced Coronary Intervention
SENIORS Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure
UKPDS UK Prospective Diabetes Study
b-PRESERVE Rationale and design of the b-blocker in heart failure with normal left ventricular ejection fraction
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for HF [22]. Studies of carvedilol also suggested a dose-
related benefit for the improvement of EF and cardiovas-
cular hospitalization and mortality rates [23, 24].
Continuation of previous b-blocker therapy after dis-
charge seems to be beneficial after acute decompensated
HF: the use of b-blockers both before admission and after
discharge was associated with lower 31- and 180-day
mortality in patients with acute decompensation receiving
b-blockers than in those who did not receive b-blocker
therapy (p\ 0.0001) [25].
A genetic component also influences responsiveness to
pharmacotherapy with b-blockers. For example, evidence
indicates that African-American patients with HF with the
GRK5 Gln41Gln genotype (and in the case of bucindolol,
also with the ADRB1 Arg389Arg genotype) especially
benefit from b-blockade [26].
2.2 Heart Failure with Preserved Ejection Fraction
The ESC and AHA guidelines primarily recommend the
use of b-blockers for the control of ventricular rate in HF
with preserved EF [12, 13].
The J-DHF trial found a favorable effect with standard
doses of carvedilol[7.5 mg/day on the endpoints of CVD
and unplanned hospitalization for any CV causes compared
with the control group (p = 0.0356). However, carvedilol
did not improve prognosis in smaller doses or in terms of
the primary outcome [27]. A predefined sub-analysis of
SENIORS also found a beneficial effect from the b1-se-
lective nebivolol in elderly patients with HF and impaired
and preserved EF on the primary endpoint of all-cause
mortality or CV hospitalization [28].
Meta-analyses of observational studies with follow-up
periods ranging mostly from 1 to 5 years have shown an
association between b-blockers and a significant (9–19%)
reduction in the relative risk (RR) of all-cause mortality in
patients with HF and preserved EF. However, the hospi-
talization rate for HF was not affected [29, 30].
These results also suggest a protective effect from b-
blocker use in this population, and the ongoing prospective
RCT of metoprolol, b-PRESERVE, will hopefully provide
enough information to enable a recommendation on the
matter [31].
2.3 Heart Failure and Chronic Kidney Disease
The beneficial effect of b-blockers on mortality and hos-
pitalization risk can also be seen in patients with HF with
reduced EF and co-existent chronic kidney disease (CKD).
A meta-analysis of six trials comparing bisoprolol, carve-
dilol, metoprolol, nebivolol, and acebutolol versus placebo
found a significant reduction of all-cause and cardiovas-
cular mortality (by 28 and 34%, respectively) [32]. A post
hoc analysis of the CAPRICORN and COPERNICUS trials
in patients with systolic left ventricular dysfunction also
found that patients with mild to moderate CKD benefited
from b-blocker therapy: carvedilol treatment decreased the
risks of all-cause, CV, and HF mortality as well as the risk
of first hospitalization for HF and the composite of CV
mortality or HF hospitalization [33]. The CIBIS-II trial
investigated patients with HF and reduced EF and found
the beneficial effect of bisoprolol on all-cause mortality
and hospitalization due to HF to be consistent irrespective
of the stage of CKD, defined by the estimated glomerular
Table 3 Outcomes of major randomized, placebo-controlled trials in patients with heart failure and reduced ejection fraction
Trial b-Blocker N Mean
duration
EF Primary endpoints Main outcomes
CIBIS-II [15] Bisoprolol 2647 1.3 years B35% All-cause mortality 11.8 vs. 17.3% (HR 0.66;
p\ 0.0001)




Carvedilol 2289 10.4 months \25% Combined risk of death or
hospitalization for CV reasons
Cumulative risk 41.6 vs.
30.2% (p = 0.00002)
Combined risk of death or
hospitalization for HF
Cumulative risk 37.9 vs.
25.5% (p = 0.000004)
MERIT-HF
[17]




SENIORS [18] Nebivolol 2128 21 months B35% in 65% of pts;
[35% in 35% of pts
Death or hospitalization for CV
reasons
31.1 vs. 35.3% (HR 0.86;
p = 0.039)
All-cause mortality 15.8 vs. 18.1% (HR 0.88;
p = 0.21)
CV cardiovascular, EF ejection fraction, HF heart failure, HR hazard ratio, pts patients
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filtration rate (eGFR). The absolute benefit of bisoprolol
was greater for patients with HF and deteriorated renal
function than for those without [34].
3 b-Blockers in Coronary Artery Disease
The majority of CV-related deaths are associated with
coronary artery disease (CAD). The last few decades has
seen a decline in CV mortality rates and a parallel increase
in prevalence rates, largely because of the increased sur-
vival rates and life expectancy of these patients [35].
The anti-anginal effect of b-blockers is mainly based on
their negative inotropic and chronotropic properties. The
decreased heart rate lessens the myocardial oxygen
demand. By prolonging the diastolic filling time and
increasing vascular resistance in non-ischemic areas, b-
blockers increase coronary perfusion of the ischemic areas
and improves the contractility of viable but hibernating
myocardial regions. The prevention of myocardial wall
stress might also contribute to the prevention of myocardial
rupture [5, 36, 37].
In patients with angina pectoris, b-blockers remain the
standard of care for the relief of symptoms and secondary
prevention of CV events. The AHA and ESC guidelines
recommend the first-line use of b-blockers in stable CAD
for heart rate and symptom control (level IA evidence) and
in patients with hypertension with chronic stable angina
and a history of prior MI (level IA evidence). b-Blocker
therapy should also be considered in asymptomatic patients
with large areas of ischemia (level IIa C evidence) and in
microvascular angina to improve effort-related angina
symptoms (level I B evidence) [37, 38]. According to the
ESC guideline on peripheral artery diseases, b-blockers are
not contraindicated in patients with LEAD and should be
considered in those with CAD (level IIa B evidence) [14].
The most frequently used agents for the management of
CAD are cardioselective b1-blockers without intrinsic
sympathomimetic activity (ISA) [37].
3.1 Stable Angina Pectoris
The use of b-blockers in patients with CAD was shown to
significantly improve exercise parameters such as time to
onset of ST-segment depression and angina, total exercise
time, and total workload. They can also reduce symp-
tomatic and asymptomatic ischemic episodes during daily
activities [39–41]. In patients with stable angina without
prior MI, b-blockers are mainly used for the relief of
angina symptoms and reduction of the ischemic burden. No
evidence is available from RCTs to support a mortality
benefit with b-blockers in patients with stable angina
pectoris without MI [42, 43]. A recent meta-analysis of
relevant b-blocker trials in patients with stable angina did
not find a significant impact of b-blockers on mortality in
general but suggested a trend for cardioselective b-blockers
to improve survival rates [44].
3.2 Myocardial Infarction
In the early large placebo-controlled RCTs in MI (includ-
ing the BHAT, the Norwegian Multicenter Study Group
Trial, and the Go¨teborg Trial), administration of b-blockers
in patients after a recent MI reduced total mortality by
25–35% [45–47]. In the first week after MI, atenolol sig-
nificantly reduced mortality by about 15% compared with
placebo in the ISIS-1 trial. Overall vascular mortality was
also significantly lower (approximately 12%) in the ate-
nolol group after 1 year [48]. The meta-analysis of 22 long-
term RCTs in MI confirmed the survival benefits of b-
blocker use with a 23% relative reduction in mortality [49].
Meta-analyses of available RCTs found a mortality
reduction of about 8–13% with administration of intra-
venous b-blocker within 24 h of acute MI [36, 50].
b-Blockers seem to have a protective effect for the
recurrence of ischemic events. The post hoc analysis of the
CHARISMA trial found a lower risk of recurrent infarction
(HR 0.62; p = 0.049) in patients with prior MI receiving b-
blocker therapy [42]. Early intravenous administration of
b-blockers might further protect from recurrent ischemic
events. Early compared with delayed administration of
metoprolol was associated with decreased incidence of re-
infarction (2.7 vs. 5.1%; p = 0.02) and recurrent ischemic
events (18.8 vs. 24.1%; p\ 0.02), although it did not
improve ventricular function or mortality rates [51]. The
COMMIT trial, investigating early intravenous and subse-
quent oral metoprolol therapy in 45,852 patients with MI,
showed that early b-blocker use reduced the risk of both re-
infarction [odds ratio (OR) 0.82; p = 0.001] and ventric-
ular fibrillation (OR 0.83; p = 0.001) [52]. A recent meta-
analysis of 16 RCTs with early intravenous b-blocker use
also confirmed a significant risk reduction for myocardial
re-infarction (RR 0.73; p = 0.004) [50].
Although the study results from COMMIT confirmed a
reduced risk of re-infarction and AF, they also suggested an
elevated risk of cardiogenic shock with the use of b-
blockers. The excess risk of shock (OR 1.30; p\ 0.00001)
was mainly observed in the first 24 h and was particularly
high in patients aged C70 years, in those with systolic
blood pressure \120 mmHg, those with a heart rate
[110 beats per minute, and those in Killip class III [52]. A
meta-analysis of 16 studies with early administration of b-
blockers did not confirm the above findings, showing no
increase in the risk of cardiogenic shock [RR 1.02, 95%
confidence interval (CI) 0.77–1.35, p = 0.91] [50]. Nev-
ertheless, caution in initiating b-blocker therapy is
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reasonable when treating high-risk patients after an MI and
those at higher risk of developing cardiogenic shock.
3.3 Coronary Artery Disease and Heart Failure
b-Blocker agents have considerable beneficial effects in
patients with HF and reduced EF after an acute MI. In the
CAPRICORN study, carvedilol significantly reduced the
risk of all-cause and cardiovascular mortality (HR 0.77,
p = 0.031; HR 0.74, p = 0.024) and the recurrence of non-
fatal MI (HR 0.71, p = 0.002) compared with placebo
[53]. A sub-analysis of SENIORS found a similar 32%
reduction in the risk of ischemic events in those with HF
and CAD treated with nebivolol after 2 years of follow-up
[54]. The MUSTT investigators also reported a similar
reduction in the 5-year mortality risk with b-blocker use in
patients with CAD and reduced EF (HR 0.63–0.72,
p\ 0.0001) [55].
Patients with HF and preserved EF after MI may also
benefit from oral b-blockers. A recent meta-analysis of
seven observational studies found a reduction in all-cause
mortality (HR 0.79, 95% CI 0.65–0.97) in patients
receiving oral b-blocker therapy after MI treated with
percutaneous coronary intervention [56].
4 b-Blockers in Atrial Fibrillation
The most common risk factors for developing AF are
hypertension, valvular disease, ischemic cardiomyopathy,
diabetes mellitus, and thyroid disease, with the majority of
patients having one or more of these conditions [57].
Agents antagonizing b-adrenergic receptors (also known
as class II antiarrhythmic drugs) decrease sympathetic
activity on the heart and prolong atrioventricular nodal
conduction time and refractoriness. These actions result in
a decreased ventricular rate in patients with AF and in the
ability to prevent the AF recurrence [58].
The ESC and AHA guidelines recommend patients with
AF be treated to achieve acute rate control and to regulate
inappropriate ventricular rate or irregular rhythm as they
can cause severe hemodynamic distress (level I A evi-
dence). Intravenous b-blocker use is recommended to slow
the ventricular heart rate in acute AF in stable patients
without pre-excitation (level I A–B evidence). Oral b-
blocker therapy is among the recommended measures to
slow the ventricular response in patients with paroxysmal,
persistent, or permanent AF (level I A–B evidence). b-
Blockers are also recommended to prevent recurrent AF in
hypertrophic cardiomyopathy and to control ventricular
rate in HF, in ACS, and in patients with hyperthyroidism
[59, 60].
4.1 Rate Control
Robust data from the AFFIRM trial confirmed b-blockers
as the most effective drugs for rate control in patients with
AF (p\ 0.0001), with overall rate control achieved in 70%
of the patients who received a b-blocker compared with
treatment initiation with a CCB or digoxin. Rate control
was considered achieved when the average resting heart
rate was B80 beats per minute and either stayed B100 for
24 h of monitoring or did not reach 110 beats per minute
after 6 min of walking [61].
A non-interventional study of patients with AF found
the risk of mortality to be lower for patients receiving rate-
control treatment with b-blockers (HR 0.76; 95% CI
0.74–0.78) compared with the control group, who did not
receive any rate-control drug [62].
A number of trials have demonstrated benefits such as
moderate heart rate and rate control with b-blocker treat-
ment in patients with HF and AF. However, the role of b-
blockers has been debated in concomitant HF and AF after
a meta-analysis of the Beta-Blockers in Heart Failure
Collaborative Group failed to show mortality reduction in
this population [63].
The BEST trial, which investigated bucindolol, showed
that, in patients with HF and reduced EF and AF, those
receiving b-blocker therapy were more likely to achieve a
resting heart rate B80 beats per minute. In all patients (with
or without AF), a resting heart rate B80 beats per minute
was correlated with a decreased risk of cardiovascular
mortality (HR 0.61, p = 0.025) and cardiovascular hospi-
talization (HR 0.79, p = 0.002) [64]. In the recently pub-
lished AF-CHF substudy, b-blocker use was also
associated with significantly lower all-cause mortality in
those with HF and AF (RR 0.72, p = 0.018), although no
effect was seen in hospitalization rate [65]. In patients with
HF and reduced EF from the Swedish Heart Failure Reg-
istry trial, b-blocker use was associated with reduced all-
cause mortality in patients with or without AF. A higher
resting heart rate was associated with increased mortality in
sinus rhythm and also in AF in patients when heart rate
exceeded[100 beats per minute [66].
Multivariate analysis of the CIBIS-II data also showed a
significant decrease of heart rate with bisoprolol compared
with placebo and an increasing mortality benefit in patients
with sinus rhythm with both lower baseline heart rates and
greater heart rate reductions during follow-up. However, no
mortality benefit was found in patients with AF [67]. The
meta-analysis of ten RCTs by the Beta-Blockers in Heart
Failure Collaborative Group showed similar results, with a
significant reduction in all-cause mortality in patients with
sinus rhythm (HR 0.73, 95% CI 0.67–0.80, p\ 0.001) but
not in patients with AF [68].
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The prospective RCT RATE-AF trial will evaluate
various effects of initial rate control therapy with biso-
prolol versus digoxin in permanent AF [69].
4.2 Prevention of Recurrent Atrial Fibrillation
The other goal of b-blocker use is to prevent the recurrence
of AF. After 6 months of follow-up, metoprolol use was
shown to significantly decrease the recurrence of AF
compared with placebo in patients enrolled after car-
dioversion of persistent AF. In those who had a relapse,
heart rate was significantly lower in the metoprolol group
[70].
In the post hoc analysis of the MERIT-HF study, b-
blocker use in patients with HF significantly reduced the
risk of new-onset AF compared with placebo (RR 0.53;
p = 0.0005) [71]. A meta-analysis of seven HF trials also
found that b-blockers significantly reduced the occurrence
of AF, with an RR reduction of 27% (p\ 0.001) [72]. The
BEST genetic substudy revealed that only patients with HF
with the Arg389Arg genotype experienced a considerable
risk reduction for new-onset AF when using bucindolol.
The ongoing GENETIC-AF study will investigate the
effect of bucindolol versus metoprolol use in ADRB1
Arg389Arg homozygous patients and hopefully shed more
light on the pharmacogenomic aspects of b-blockade [26].
In terms of survival, data from the COMET study indicated
that new-onset AF is an independent predictor of long-term
all-cause mortality in patients with HF [73].
In patients after MI with left ventricular dysfunction, b-
blocker use substantially reduced the incidence of AF or
flutter (HR 0.41; p = 0.0003); the corresponding risk of
ventricular tachyarrhythmia was even lower (HR 0.24;
p\ 0.0001) [74].
b-Blockers effectively prevent postoperative AF, the
most common complication of cardiac surgery. Robust
meta-analyses of RCTs found a risk reduction of AF after
cardiac surgery of 66–74% with b-blockers [75–78].
Advantages of perioperative use of b-blockers in non-car-
diac surgery are less clear. Systematic reviews have shown
that, although b-blockers significantly reduced the occur-
rence of AF, myocardial ischemia, and acute MI, they may
also incur a potential increase in all-cause mortality and
cerebrovascular events [79, 80].
4.3 Atrial Fibrillation and Hyperthyroidism
Atrial fibrillation is a common finding in hyperthyroid
states (encountered in 10–15% of the patients) [81]. In
those with thyrotoxicosis, treatment with b-blockers not
only significantly decreased heart rate and systolic blood
pressure but also improved other hyperadrenergic symp-
toms such as muscle weakness, tremor, degree of
irritability, emotional lability, and exercise intolerance
[82–85].
5 b-Blockers in Diabetes Mellitus and Metabolic
Syndrome
Diabetes mellitus (DM) and obesity are highly correlated
with CVD and associated with an increased risk of devel-
oping major CV events, including CAD, stroke, and HF;
the risk is further exacerbated in those with concomitant
hypertension. Both metabolic syndrome and DM are
associated with high adrenergic drive and cardiac output,
resulting in myocardial and vascular damage. Conse-
quently, the risk of mortality due to heart disease and
ischemic heart disease is two to four times higher for
patients with DM than for those without [86–88].
Despite the supporting facts and guidelines, there is still
reluctance to prescribe b-blockers in patients with DM and
CVD, especially among patients with the most severe,
high-risk disease, who could benefit the most from appro-
priate therapy [89, 90].
Concerns have been raised regarding the use of b-
blockers in the diabetic population or in those at increased
risk of DM due to a possible deteriorating metabolic
influence of some of these agents. Furthermore, the risk of
prolonged hypoglycemia was hypothesized to be higher
with non-selective b-blockade in patients using insulin or
sulfonylureas. However, no significant difference could be
seen in the risk of hypoglycemia with b-blockers in a
cohort of 13,559 elderly patients with DM compared with
non-users. Only a non-significant trend favoring cardiose-
lective over non-selective b-blockers was registered
[86, 91].
Metabolic changes attributable to b-blockers may
include elevation of blood sugar and glycated hemoglobin
(HbA1c) levels, worsening of insulin sensitivity, and
changes in triglyceride and lipoprotein levels and seem to
be mainly associated with b2 and b3 receptor blockade
[86, 92]. Consequently, while non-selective agents may
cause deterioration of metabolic parameters, these distur-
bances are observed to a much lesser extent with b1-se-
lective agents (e.g., atenolol or bisoprolol) and cannot be
observed with vasodilator agents, including those with
intrinsic b2 sympathomimetic activity (e.g., nebivolol) or
triggering a-blockade (e.g., carvedilol) [86, 91, 93–99].
According to the ESH/ESC guidelines, all classes of
antihypertensive agents are recommended and can be used
in patients with hypertension and DM (level I A evidence).
In those with metabolic syndrome, antihypertensive agents
that potentially improve or at least do not worsen insulin
sensitivity (including vasodilating b-blockers) should be
considered (level IIa C evidence) [2]. The ESC guidelines
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do not contraindicate b-blocker use for hypertension in
patients with LEAD and DM, based on the finding that b-
blockers do not adversely affect walking capacity or
symptoms of intermittent claudication in patients with
mild-to-moderate LEAD [2, 14]. Evidence on the use of
various anti-hypertensive drugs in peripheral artery disease
is generally poor. Therefore, careful consideration of
individual patient therapy should be made on a case-by-
case basis.
The American Association of Clinical Endocrinologists
(AACE) guidelines find b-blockers to be less appealing for
first-line treatment of hypertension in patients with DM
(grade A recommendation). The use of third-generation b-
blockers that cause vasodilatation and an increase in insulin
sensitivity (such as nebivolol or carvedilol) seem to be
particularly beneficial (grade A recommendation) [100].
In DM with systolic HF, a b-blocker is recommended to
reduce mortality and hospitalization according to the joint
ESC/EASD guidelines (level I A evidence). In DM with an
ACS, b-blockers should be considered to reduce mortality
and morbidity (level IIa B evidence). b-Blockers are also
recommended in both HF and after acute MI to prevent
sudden cardiac death in patients with DM (level I A evi-
dence) [101].
5.1 Diabetes Mellitus and Hypertension
Although the use of b-blockers has been associated with an
increased risk of developing type 2 DM, the influence of
adverse metabolic effects seems to be much smaller in
those with established and adequately treated DM com-
pared with the several benefits of blood pressure control in
those with concomitant hypertension [101–103].
A sub-study of the UKPDS evaluated the long-term
impact of blood pressure control in hypertension and with
DM. The use of atenolol or captopril significantly reduced
the risk of fatal (32%) and non-fatal (24%) macrovascular
and microvascular complications over 9 years of follow-up
in the tight blood pressure control group (aiming for a
blood pressure of \150/85 mmHg), with equal efficacy
between the agents studied. The trial not only found mor-
tality and morbidity benefits of a b1-selective blocker to be
similar to those of an ACE inhibitor in patients with DM
but also found that tight blood pressure control may be
more important than glycemic control in protecting these
patients against macrovascular and microvascular disease
as well as possibly considerably improving their survival
[103, 104].
5.2 Diabetes Mellitus and Heart Failure
Meta-analyses of major HF trials (Australia/New Zealand
Heart Failure Research Collaborative Group, BEST,
CAPRICORN, CIBIS-II, COPERNICUS, MERIT-HF,
MOCHA, PRECISE, US Carvedilol Trials) indicate a
similar and significant survival benefit with b-blockers
compared with placebo in diabetic and non-diabetic pop-
ulations (ranging from 16 to 28% and from 28 to 37%,
respectively), with consistently overlapping 95% CIs of
risk ratios through the analyses. The relative reduction in
mortality shows a less favorable trend for patients with
diabetes compared with those without. However, as the
absolute risk of mortality is considerably greater in patients
with DM, the absolute mortality benefit should be equal or
even greater for those with DM [87, 105–107]. Subgroup
analyses of individual major HF trials also show a similar
reduction in hospitalization and improvement of symptoms
in those with and without DM [15, 108–110].
5.3 Diabetes Mellitus and Myocardial Infarction
In post-MI patients with DM, b-blockers were shown to
reduce the risk of late infarction, sudden death, and
arrhythmias and to improve mortality according to ret-
rospective analyses of the MIAMI study and the Go¨te-
borg Metoprolol Trial [111]. Data from a multicenter
cohort of 2024 patients indicated that b-blocker use is an
independent predictor of 1-year cardiac survival fol-
lowing hospital discharge for post-MI patients with DM.
Patients with DM receiving b-blocker therapy had a
mortality of 10% compared with 23% for those who did
not receive a b-blocker [112]. In a retrospective analysis
of patients with CAD and non-insulin-dependent DM
from the BIP study, those receiving b-blocker therapy
had a reduced mortality risk (RR 0.58; p = 0.0001) after
3 years of follow-up than those without b-blocker med-
ication [113].
A large observational study including 59,445 patients
with DM showed a 36% mortality reduction 2 years after
MI in those treated with a b-blocker. The mortality
reduction in patients with no complications was 40%.
Again, though the relative benefit compared with patients
without DM seems to be somewhat smaller, due to the high
mortality rate among patients with DM after MI, the
absolute survival benefit is expected to be much larger in
patients with DM [87, 89].
6 b-Blockers in Chronic Obstructive Pulmonary
Disease and Bronchial Asthma
Cardiovascular disease frequently coexist with chronic
obstructive pulmonary disease (COPD). However, b-
blockers are substantially underused in patients with both
COPD and CVD for fear of adverse pulmonary effects,
especially in advanced COPD [114, 115]. b-Blockers are
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generally considered to be contraindicated in patients with
bronchial asthma [116].
Because of the very sensitive feedback mechanism of
the adrenergic system, chronic use of b-blockers sensitizes
the b2 receptors to further stimulation by increasing
receptor density in target tissues. Consequently, b-blockers
may even improve the effectiveness of b2 agonists during
an exacerbation of reactive airway disease by potentiating
their bronchodilator effects. This is a counterintuitive
therapeutic approach and has not yet been widely investi-
gated. The b2-blocking effect of cardioselective b-blockers
is negligible in therapeutic doses; therefore, there should be
no increase in the risk of bronchoconstriction with their use
[117].
According to recommendations from the Global Initia-
tive for Chronic Obstructive Pulmonary Disease (GOLD),
hypertension, HF, CAD, and AF should be treated
according to usual guidelines even in patients with severe
COPD. If b-blockers are indicated, a selective b1-blocker
(i.e., bisoprolol, metoprolol, or nebivolol) should be chosen
and non-selective blockers avoided, especially in higher
doses [118]. The ESC guidelines for HF also encourage the
use of selective b1-blockers in HF with COPD [12]. The
Global Initiative for Asthma (GINA) recommendations do
not encourage the use of b-blockers in patients with
bronchial asthma; if necessary, treatment should be started
under close medical supervision and decisions made on a
case-by-case basis (level D evidence). Asthma is not an
absolute contraindication for cardioselective b-blockers for
acute coronary events, but a careful risk–benefit assessment
should be undertaken (level D evidence) [119].
A Cochrane review of 29 RCTs of cardioselective b1-
blockers found no adverse respiratory effects in the short
term in mild-moderate reversible airway disease or COPD.
b1-Blockers without ISA even showed a nonsignificant
trend for increase in respiratory function after b2-agonist
administration compared with placebo [116].
A Cochrane review of 22 RCTs of b1-selective b-
blockers found no adverse effect on lung function or res-
piratory symptoms compared with placebo in COPD, even
in severe chronic airway obstruction or disease with a
reversible obstructive component [114].
A prospective multicenter observational study of current
and former smokers found b-blockers to be associated with
a significant reduction in COPD exacerbations regardless
of the severity of airflow obstruction [incidence risk ratio
(IRR) 0.73, p = 0.003]. The use of other medications for
CVD such as CCBs and ACE inhibitors or ARBs was not
associated with a reduction in exacerbation risk [120].
Another study found b-blockers to reduce all-cause mor-
tality and COPD exacerbations when added to established
COPD therapy. The additive benefits of b-blockers were
independent of other CV drugs and history of overt CVD
[121].
A number of observational studies found a survival
benefit with b-blocker use in patients with HF and/or after
MI [122–125]. In patients with HF and COPD, the use of
the b1-selective bisoprolol reduced mortality (especially at
higher doses) as well as the incidence of congestive HF and
COPD exacerbations [122, 123].
Although the observational studies even suggest some
benefit with b-blockers in COPD, RCTs to confirm these
findings are lacking. Patients with COPD should not be
denied b-blocker treatment, but careful titration and the use
of agents with b1-selectivity is advised. In bronchial
asthma, a benefit-to-risk ratio should be evaluated on an
individual basis and b-blockers avoided if possible.
7 Conclusions
The efficacy of b-blockers has been well demonstrated
in several CVDs. These agents were found to consid-
erably reduce mortality in HF with reduced EF, in CAD
after a MI, and in complicated CVDs, for example with
CKD or DM. b-Blockers may also be beneficial in HF
with preserved EF. Furthermore, b-blockers improve
several symptoms of stable angina pectoris and thyro-
toxicosis, provide rate control, and prevent new-onset
or recurrent AF in HF, after MI, and following cardiac
surgery.
High-risk CV with several comorbidities may also
benefit from therapy with b-blockers. In some cases, such
as CAD or hypertension complicated with DM, the choice
of cardioselective b-blockers or agents with vasodilator
activity may be preferable. In CVD complicated with
COPD, a b1-blocker should be the drug of choice when
indicated.
Clinical guidelines based on solid evidence give clear
recommendations in all the conditions discussed herein.
Therapeutic decisions should be evidence based, and
patients should not be denied treatment based on personal
preconceptions.
The final chapter of the history of b-blockers has not yet
been written. Robust prospective studies are ongoing that
will hopefully resolve some of the still divisive issues
regarding b-blockers. Personalized pharmacogenomic
approaches might be the way of optimizing CV therapy in
future.
Compliance with Ethical Standards
The authors take responsibility for all aspects of the reliability and
freedom from bias of the data presented and their discussed
interpretation.
The Real Role of b-Blockers in Daily Cardiovascular Therapy
Funding No external funding was used in the preparation of this
manuscript.
Conflict of interest Csaba Andra´s De´zsi and Veronika Szentes have
no conflicts of interest that are directly relevant to the contents of this
manuscript.
Open Access This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/by-nc/4.0/), which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made.
References
1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart Disease and
Stroke Statistics—2010 update. A Report From the American
Heart Association. Circulation. 2010;121:e1–170.
2. Taylor J, et al. 2013 ESH/ESC Guidelines for the management
of arterial hypertension. Eur Heart J. 2013;34(28):2108–9.
3. Wiysonge CS, Bradley HA, Volmink J, et al. Beta-blockers for
hypertension. Cochrane Database Syst Rev. 2012;11:CD002003.
4. Bui AL, Horwich TB, Fonarow GC, et al. Epidemiology and risk
profile of heart failure. Nat Rev Cardiol. 2011;8(1):30–41.
5. Gheorghiade M, Colucci WS, Swedberg K. b-Blockers in
chronic heart failure. Circulation. 2003;107:1570–5.
6. Wilcox CS, Tisher CC. Handbook of nephrology and hyper-
tension. Philadelphia: Lippincott Williams & Wilkins; 2008.
7. Chatterjee S, Biondi-Zoccai G, Abbate A, et al. Benefits of b
blockers in patients with heart failure and reduced ejection
fraction: network meta-analysis. BMJ. 2013;346:f55.
8. Doughty RN, MacMahon S, Sharpe N, et al. Beta-blockers in
heart failure: promising or proved? J Am Coll Cardiol.
1994;23(3):814–21.
9. Lechat P, Packer M, Chalon S, et al. Beta-blockers in heart
failure: meta-analysis of randomized trials. Circulation.
1998;98:1184–91.
10. Marazzi G, Volterrani M, Caminiti G, et al. Comparative long
term effects of nebivolol and carvedilol in hypertensive heart
failure patients. J Cardiac Fail. 2011;17(9):703–9.
11. Nodari S, Metra M, Dei Cas L. b-Blocker treatment of patients
with diastolic heart failure and arterial hypertension. A
prospective, randomized, comparison of the long-term effects of
atenolol vs. nebivolol. Eur J Heart Fail. 2003;5:621–7.
12. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines
for the diagnosis and treatment of acute and chronic heart failure
2012: the Task Force for the Diagnosis and Treatment of Acute
and Chronic Heart Failure 2012 of the European Society of
Cardiology. Developed in collaboration with the Heart Failure
Association (HFA) of the ESC. Eur Heart J. 2012;33(14):
1787–847.
13. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA
guideline for the management of heart failure: a report of the
American College of Cardiology Foundation/American Heart
Association Task Force on practice guidelines. Circulation.
2013;128(16):e240–327.
14. Tendera M, Aboyans V, Bartelink ML, et al. ESC Guidelines on
the diagnosis and treatment of peripheral artery diseases: doc-
ument covering atherosclerotic disease of extracranial carotid
and vertebral, mesenteric, renal, upper and lower extremity
arteries: the Task Force on the Diagnosis and Treatment of
Peripheral Artery Diseases of the European Society of Cardi-
ology (ESC). Eur Heart J. 2011;32(22):2851–906.
15. CIBIS-II Investigators and Committees. The Cardiac Insuffi-
ciency Bisoprolol Study II (CIBIS-II): a randomised trial. Lan-
cet. 1999;353(9146):9–13.
16. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol
on the morbidity of patients with severe chronic heart failure.
Results of the carvedilol prospective randomized cumulative
survival (COPERNICUS) study. Circulation.
2002;106:2194–9.
17. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of con-
trolled-release metoprolol on total mortality, hospitalizations,
and well-being in patients with heart failure: the Metoprolol CR/
XL Randomized Intervention Trial in congestive heart failure
(MERIT-HF). MERIT-HF Study Group. JAMA. 2000;283(10):
1295–302.
18. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to
determine the effect of nebivolol on mortality and cardiovas-
cular hospital admission in elderly patients with heart failure
(SENIORS). Eur Heart J. 2005;26:215–25.
19. Doughty RN, Rodgers A, Sharpe N, et al. Effects of beta-blocker
therapy on mortality in patients with heart failure. A systematic
overview of randomized controlled trials. Eur Heart J.
1997;18:560–5.
20. Heidenrich PA, Lee TT, Massie BM. Effect of beta-blockade on
mortality in patients with heart failure: a meta-analysis of ran-
domized clinical trials. J Am Coll Cardiol. 1997;30:27–34.
21. Poole-Wilson PA, Swedberg K, Cleland JGF, et al. Comparison
of carvedilol and metoprolol on clinical outcomes in patients
with chronic heart failure in the Carvedilol Or Metoprolol
European Trial (COMET): randomised controlled trial. Lancet.
2003;362:7–13.
22. Lin TY, Chen CY, Huang YB. Evaluating the effectiveness of
different beta-adrenoceptor blockers in heart failure patients. Int
J Cardiol. 2017;230:378–83.
23. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol pro-
duces dose-related improvements in left ventricular function and
survival in subjects with chronic heart failure. Circulation.
1996;94:2807–16.
24. Hori M, Sasayama S, Kitabatake A, et al. Low-dose carvedilol
improves left ventricular function and reduces cardiovascular
hospitalization in Japanese patients with chronic heart failure:
the Multicenter Carvedilol Heart Failure Dose Assessment
(MUCHA) trial. Am Heart J. 2004;147(2):324–30.
25. Bo¨hm M, Link A, Cai D, et al. Beneficial association of b-
blocker therapy on recovery from severe acute heart failure
treatment: data from the Survival of Patients With Acute Heart
Failure in Need of Intravenous Inotropic Support trial. Crit Care
Med. 2011;39(5):940–4.
26. Turner RM, Pirmohamed M. Cardiovascular pharmacoge-
nomics: expectations and practical benefits. Clin Pharmacol
Ther. 2014;95(3):281–93.
27. Yamamoto K, Origasa H, Hori M, et al. Effects of carvedilol on
heart failure with preserved ejection fraction: the Japanese
Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail.
2013;15(1):110–8.
28. van Veldhuisen DJ, Cohen-Solal A, Bohm M, et al. Beta-
blockade with nebivolol in elderly heart failure patients with
impaired and preserved left ventricular ejection fraction: data
from SENIORS (Study of Effects of Nebivolol Intervention on
Outcomes and Rehospitalization in Seniors With Heart Failure).
J Am Coll Cardiol. 2009;53:2150–8.
29. Bavishi C, Chatterjee S, Ather S, et al. Beta-blockers in heart
failure with preserved ejection fraction: a meta-analysis. Heart
Fail Rev. 2015;20:193–201.
C. A. De´zsi, V. Szentes
30. Liu F, Chen Y, Feng X, et al. Effects of beta-blockers on heart
failure with preserved ejection fraction: a meta-analysis. PLoS
One. 2014;9(3):e90555.
31. Zhou J, Shi H, Zhang J, et al. Rationale and design of the beta-
blocker in heart failure with normal left ventricular ejection
fraction (beta-PRESERVE) study. Eur J Heart Fail. 2010;12(2):
181–5.
32. Badve SV, Roberts MA, Hawley CM, et al. Effects of beta-
adrenergic antagonists in patients with chronic kidney disease. A
systematic review and meta-analysis. J Am Coll Cardiol.
2011;58:1152–61.
33. Wali RK, Iyengar M, Beck GJ, et al. Efficacy and safety of
carvedilol in treatment of heart failure with chronic kidney
disease a meta-analysis of randomized trials. Circ Heart Fail.
2011;4:18–26.
34. Castagno D, Jhund PS, McMurray JJ, et al. Improved survival
with bisoprolol in patients with heart failure and renal impair-
ment: an analysis of the cardiac insufficiency bisoprolol study II
(CIBIS-II) trial. Eur J Heart Fail. 2010;12:607–16.
35. Barsness GW, Holmes DR Jr, editors. Coronary Artery Disease:
New Approaches without Traditional Revascularization. Lon-
don: Springer; 2011.
36. Held PH, Yusuf S. Effects of beta-blockers and calcium channel
blockers in acute myocardial infarction. Eur Heart J. 1993;14
Suppl F:18–25.
37. Rosendorff C, Lackland DT, Allison M, et al. Treatment of
hypertension in patients with coronary artery disease. A scien-
tific statement from the American Heart Association, American
College of Cardiology, and American Society of Hypertension.
Hypertension. 2015;65:1372–407.
38. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC
guidelines on the management of stable coronary artery disease.
The Task Force on the management of stable coronary artery
disease of the European Society of Cardiology. Eur Heart J.
2013;34(38):2949–3003.
39. de Vries RJ, van den Heuvel AF, Lok DJ, et al. Nifedipine
gastrointestinal therapeutic system versus atenolol in
stable angina pectoris. The NetherlandsWorking Group on
Cardiovascular Research (WCN). Int J Cardiol.
1996;57:143–50.
40. Fox KM, Mulcahy D, Findlay I, et al. The Total Ischaemic
Burden European Trial (TIBET). Effects of atenolol, nifedipine
SR and their combination on the exercise test and the total
ischaemic burden in 608 patients with stable angina. The TIBET
Study Group. Eur Heart J. 1996;17:96–103.
41. van de Ven LL, Vermeulen A, Tans JG, et al. Which drug to
choose for stable angina pectoris: a comparative study between
bisoprolol and nitrates. Int J Cardiol. 1995;47:217–23.
42. Bangalore S, Bhatt DL, Steg PG, et al. b-Blockers and cardio-
vascular events in patients with and without myocardial
infarction. Post hoc analysis from the CHARISMA Trial. Circ
Cardiovasc Qual Outcomes. 2014;7:872–81.
43. Husted SE, Ohman EM. Pharmacological and emerging thera-
pies in the treatment of chronic angina. Lancet. 2015;386:
691–701.
44. Huang HL, Fox KA. The impact of beta-blockers on mortality in
stable angina: a meta-analysis. Scott Med J. 2012;57(2):69–75.
45. b-Blocker Heart Attack Trial Research Group. A randomized
trial of propranolol in patients with acute myocardial infarction,
I: mortality results. JAMA. 1982;247:1707–14.
46. Hjalmarson A, Herlitz J, Holmberg S, et al. The Go¨teborg
metoprolol trial. Effects on mortality and morbidity in acute
myocardial infarction. Circulation. 1983;67(6 Pt 2):I26–32.
47. The Norwegian Multicenter Study Group. Timolol-induced
reduction in mortality and reinfarction in patients surviving
acute myocardial infarction. N Engl J Med. 1981;304:801–7.
48. First International Study of Infarct Survival Collaborative
Group. Randomised trial of intravenous atenolol among 16 027
cases of suspected acute myocardial infarction: ISIS-1. Lancet.
1986;2(8498):57–66.
49. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after
myocardial infarction: an overview of the randomized trials.
Prog Cardiovasc Dis. 1985;27(5):335–71.
50. Chatterjee S, Chaudhuri D, Vedanthan R, et al. Early intra-
venous beta-blockers in patients with acute coronary syn-
drome—a meta-analysis of randomized trials. Int J Cardiol.
2013;168(2):915–21.
51. Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus
deferred beta-blockade following thrombolytic therapy in
patients with acute myocardial infarction. Results of the
Thrombolysis in Myocardial Infarction (TIMI) II-B Study.
Circulation. 1991;83(2):422–37.
52. Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral
metoprolol in 45 852 patients with acute myocardial infarction:
randomised placebo controlled trial. Lancet. 2005;366:1622–32.
53. Dargie HJ, et al. Effect of carvedilol on outcome after
myocardial infarction in patients with left-ventricular dysfunc-
tion: the CAPRICORN randomised trial. Lancet. 2001;357:
1385–90.
54. Ambrosio G, Flather MD, Bo¨hm M, et al. b-Blockade with
nebivolol for prevention of acute ischaemic events in elderly
patients with heart failure. Heart. 2011;97:209–14.
55. Ellison KE, Hafley GE, Hickey K, et al. Effect of b-blocking
therapy on outcome in the Multicenter UnSustained Tachycardia
Trial (MUSTT). Circulation. 2002;106:2694–9.
56. Misumida N, Harjai K, Kernis S, et al. Does oral beta-blocker
therapy improve long-term survival in ST-segment elevation
myocardial infarction with preserved systolic function? A meta-
analysis. J Cardiovasc Pharmacol Ther. 2016;21(3):280–5.
57. Schoonderwoerd BA, Smit MD, Pen L, et al. New risk factors
for atrial fibrillation: causes of ‘not-so-lone atrial fibrillation’.
Europace. 2008;10(6):668–73.
58. Gussak I, Antzelevitch C, Wilde AAM, et al., editors. Electrical
diseases of the heart: genetics, mechanisms, treatment, preven-
tion. London: Springer; 2013.
59. Camm AJ, Lip GY, De Caterina R, et al. Guidelines for the
management of atrial fibrillation. The Task Force for the Man-
agement of Atrial Fibrillation of the European Society of Car-
diology (ESC). Eur Heart J. 2010;31:2369–429.
60. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS
guideline for the management of patients with atrial fibrillation:
executive summary: a report of the American College of Car-
diology/American Heart Association Task Force on Practice
Guidelines and the Heart Rhythm Society. Circulation.
2014;130(23):2071–104.
61. Olshansky B, Rosenfeld LE, Warner AL, et al. The atrial fib-
rillation follow-up investigation of rhythm management
(AFFIRM) study. Approaches to control rate in atrial fibrillation.
J Am Coll Cardiol. 2004;43(7):1201–8.
62. Chao T, Liu C, Tuan C, et al. Rate-control treatment and mor-
tality in atrial fibrillation. Circulation. 2015;132:1604–12.
63. Piccini JP, Allen LA. Heart failure complicated by atrial fibril-
lation. Don’t bury the beta-blockers just yet. JACC Heart Fail.
2017.
64. Kao DP, Davis G, Aleong R, et al. Effect of bucindolol on heart
failure outcomes and heart rate response in patients with reduced
ejection fraction heart failure and atrial fibrillation. Eur J Heart
Fail. 2013;15:324–33.
65. Cadrin-Tourigny J, Shohoudi A, Roy D, et al. Decreased mor-
tality with beta-blockers in patients with heart failure and
coexisting atrial fibrillation: an AF-CHF substudy. JACC Heart
Fail. 2017.
The Real Role of b-Blockers in Daily Cardiovascular Therapy
66. Li SJ, Sartipy U, Lund LH, et al. Prognostic significance of
resting heart rate and use of b-blockers in atrial fibrillation and
sinus rhythm in patients with heart failure and reduced ejection
fraction. Findings from the Swedish Heart Failure Registry. Circ
Heart Fail. 2015;8(5):871–9.
67. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac
rhythm relationships with bisoprolol benefit in chronic heart
failure in CIBIS II Trial. Circulation. 2001;103(10):1428–33.
68. Kotecha D, Holmes J, Krum H, et al. Efficacy of b blockers in
patients with heart failure plus atrial fibrillation: an individual-
patient data meta-analysis. Lancet. 2014;384:2235–43.
69. University of Birmingham. Rate control therapy evaluation in
permanent atrial fibrillation (RATE-AF) [ClinicalTrials.gov iden-
tifier NCT02391337]. US National Institutes of Health, Clini-
calTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02391337.
70. Ku¨hlkamp V, Schirdewan A, Stangl K, et al. Use of metoprolol
CR/XL to maintain sinus rhythm after conversion from persis-
tent atrial fibrillation. A randomized, double-blind, placebo-
controlled study. J Am Coll Cardiol. 2000;36(1):139–46.
71. van Veldhuisen DJ, Aass H, El Allaf D, et al. Presence and
development of atrial fibrillation in chronic heart failure: expe-
riences from the MERIT-HF Study. Eur J Heart Fail.
2006;8(5):539–46.
72. Nasr IA, Bouzamondo A, Hulot JS, et al. Prevention of atrial
fibrillation onset by beta-blocker treatment in heart failure: a
meta-analysis. Eur Heart J. 2007;28(4):457–62.
73. Swedberg K, Olsson LG, Charlesworth A, et al. Prognostic
relevance of atrial fibrillation in patients with chronic heart
failure on long-term treatment with beta-blockers: results from
COMET. Eur Heart J. 2005;26(13):1303–8.
74. McMurray J, Køber L, Robertson M, et al. Antiarrhythmic effect
of carvedilol after acute myocardial infarction: results of the
Carvedilol Post-Infarct Survival Control in Left Ventricular
Dysfunction (CAPRICORN) trial. J Am Coll Cardiol.
2005;45(4):525–30.
75. Arsenault KA, Yusuf AM, Crystal E, et al. Interventions for
preventing post-operative atrial fibrillation in patients undergo-
ing heart surgery (review). Cochrane Database Syst Rev.
2013;1:003611.
76. Burgess DC, Kilborn MJ, Keech AC, et al. Interventions for
prevention of post-operative atrial fibrillation and its complica-
tions after cardiac surgery: a meta-analysis. Eur Heart J.
2006;27(23):2846–57.
77. Sakamoto A, Hamasaki T, Kitakaze M, et al. Perioperative
landiolol administration reduces atrial fibrillation after cardiac
surgery: a meta-analysis of randomized controlled trials. Adv
Ther. 2014;31(4):440–50.
78. Wang HS, Wang ZW, Yin ZT, et al. Carvedilol for prevention of
atrial fibrillation after cardiac surgery: a meta-analysis. PLoS
One. 2014;9(4):e94005.
79. Blessberger H, Kammler J, Domanovits H, et al. Perioperative
beta-blockers for preventing surgery-related mortality and
morbidity. Cochrane Database Syst Rev. 2014;9:004476.
80. Wijeysundera DN, Duncan D, Nkonde-Price C, et al. Perioper-
ative beta blockade in noncardiac surgery: a systematic review
for the 2014 ACC/AHA guideline on perioperative cardiovas-
cular evaluation and management of patients undergoing non-
cardiac surgery. A Report of the American College of
Cardiology/American Heart Association Task Force on Practice
Guidelines. Circulation. 2014;130(24):2246–64.
81. Gu¨rdog˘an M, Ari H, Tenekeciog˘lu E, et al. Predictors of atrial
fibrillation recurrence in hyperthyroid and euthyroid patients.
Arq Bras Cardiol. 2016;106(2):84–91.
82. Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism
and other causes of thyrotoxicosis: management guidelines of
the American Thyroid Association and American Association of
Clinical Endocrinologists. Thyroid. 2011;21(6):593–646.
83. Tagami T, Yambe Y, Tanaka T, et al. Short-term effects of b-
adrenergic antagonists and methimazole in new-onset thyro-
toxicosis caused by Graves’ disease. Intern Med.
2012;51(17):2285–90.
84. Trzepacz PT, Klein I, Roberts M, et al. Graves’ disease: an
analysis of thyroid hormone levels and hyperthyroid signs and
symptoms. Am J Med. 1989;87(5):558–61.
85. Ventrella SM, Klein I. Beta-adrenergic receptor blocking drugs
in the management of hyperthyroidism. Endocrinologist.
1994;4(5):391–9.
86. Cruickshank JM. Are we misunderstanding beta-blockers. Int J
Cardiol. 2007;120(1):10–27.
87. Aubert R. Diabetes in America. DIANE Publishing, 2nd edition.
NIH Publication No. 95-1468. National Institutes of Health,
National Institute of Diabetes and Digestive and Kidney Dis-
eases; 1995.
88. Jacob S, Rett K, Henriksen EJ, et al. Antihypertensive therapy
and insulin sensitivity: do we have to redefine the role of beta
blocking agents? Am J Hypertens. 1998;11(10):1258–65.
89. Gottlieb S, McCarter RJ, Vogel RA, et al. Effect of beta-
blockade on mortality among high-risk and low-risk patients
after myocardial infarction. N Engl J Med. 1998;339(8):489–97.
90. Landray MJ, Toescu V, Kendall MJ, et al. The cardioprotective
role of b-blockers in patients with diabetes mellitus. J Clin
Pharm Ther. 2002;27(4):233–42.
91. Shorr RI, Ray WA, Daugherty JR, et al. Antihypertensives and
the risk of serious hypoglycemia in older persons using insulin
or sulfonylureas. JAMA. 1997;278(1):40–3.
92. Hirst JA, Farmer AJ, Feakins BG, et al. Quantifying the effects
of diuretics and b-adrenoceptor blockers on glycaemic control in
diabetes mellitus—a systematic review and meta-analysis. Br J
Clin Pharmacol. 2015;79(5):733–43.
93. Dominguez LJ, Barbagallo M, Jacober SJ, et al. Bisoprolol and
captopril effects on insulin receptor tyrosine kinase activity in
essential hypertension. Am J Hypertens. 1997;10:1349–55.
94. Kostis JB, Sanders M. The association of heart failure with
insulin resistance and the development of type 2 diabetes. Am J
Hypertens. 2005;18:731–7.
95. Ladage D, Reidenbach C, Rieckeheer E, et al. Nebivolol lowers
blood pressure and increases weight loss in patients with
hypertension and diabetes in regard to age. J Cardiovasc Phar-
macol. 2010;56(3):275–81.
96. Poirier L, Cle´roux J, Nadeau A, et al. Effects of nebivolol and
atenolol on insulin sensitivity and haemodynamics in hyper-
tensive patients. J Hypertens. 2001;19(8):1429–35.
97. Rosendorff C. Beta-blocking agents with vasodilator activity.
J Hypertens. 1993;11(4):S37–40.
98. Seguchi H, Nakamura H, Aosaki N, et al. Effects of carvedilol
on serum lipids in hypertensive and normotensive subjects. Eur J
Clin Pharmacol. 1990;38(Suppl 2):S139–42.
99. Wang B, Song WH, Liu GZ, et al. The effect long-term
administration of a selective beta1 blocker bisoprolol on glucose
metabolism in patients with essential hypertensive and type 2
diabetes mellitus. Zhonghua Nei Ke Za Zhi. 2005;44(7):503–5.
100. Torre JJ, Bloomgarden ZT, Dickey RA, et al. American Asso-
ciation of Clinical Endocrinologists Medical guidelines for
clinical practice for the diagnosis and treatment of hypertension.
Endocr Pract. 2006;12(2):193–222.
101. Ryde´n L, Grant PJ, Anker SD, et al. ESC Guidelines on dia-
betes, pre-diabetes, and cardiovascular diseases developed in
collaboration with the EASD: the Task Force on diabetes, pre-
diabetes, and cardiovascular diseases of the European Society of
Cardiology (ESC) and developed in collaboration with the
C. A. De´zsi, V. Szentes
European Association for the Study of Diabetes (EASD). Eur
Heart J. 2013;34(39):3035–87.
102. Bangalore S, Parkar S, Grossman E, et al. A meta-analysis of
94,492 patients with hypertension treated with beta blockers to
determine the risk of new-onset diabetes mellitus. Am J Cardiol.
2007;100(8):1254–62.
103. UK Prospective Diabetes Study Group. Tight blood pressure
control and risk of macrovascular and microvascular compli-
cations in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):
703–13.
104. UK Prospective Diabetes Study Group. Efficacy of atenolol and
captopril in reducing risk of macrovascular and microvascular
complications in type 2 diabetes: UKPDS 39. BMJ.
1998;317(7160):713–20.
105. Bell DS, Lukas MA, Holdbrook FK, et al. The effect of carve-
dilol on mortality risk in heart failure patients with diabetes:
results of a meta-analysis. Curr Med Res Opin.
2006;22(2):287–96.
106. Haas SJ, Vos T, Gilbert RE, et al. Are beta-blockers as effica-
cious in patients with diabetes mellitus as in patients without
diabetes mellitus who have chronic heart failure? A meta-anal-
ysis of large-scale clinical trials. Am Heart J. 2003;146(5):
848–53.
107. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angio-
tensin-converting enzyme inhibitors and beta-blockers in the
management of left ventricular systolic dysfunction according to
race, gender and diabetic status: a meta-analysis of major clin-
ical trials. J Am Coll Cardiol. 2003;41(9):1529–38.
108. Deedwania PC, Giles TD, Klibaner M, et al. Efficacy, safety and
tolerability of metoprolol CR/XL in patients with diabetes and
chronic heart failure: experiences from MERIT-HF. Am Heart J.
2005;149(1):159–67.
109. Domanski M, Krause-Steinrauf H, Deedwania P, et al. The
effect of diabetes on outcomes of patients with advanced heart
failure in the BEST trial. J Am Coll Cardiol. 2003;42(5):914–22.
110. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on
survival in severe chronic heart failure. N Engl J Med.
2001;344(22):1651–8.
111. Malmberg K, Herlitz J, Hjalmarson A, et al. Effects of meto-
prolol on mortality and late infarction in diabetics with sus-
pected acute myocardial infarction. Retrospective data from two
large studies. Eur Heart J. 1989;10(5):423–8.
112. Kjekshus J, Gilpin E, Cali G, et al. Diabetic patients and beta-
blockers after acute myocardial infarction. Eur Heart J.
1990;11:43–50.
113. Jonas M, Reicher-Reiss H, Boyko V, et al. Usefulness of beta-
blocker therapy in patients with non-insulin-dependent diabetes
mellitus and coronary artery disease. Bezafibrate Infarction
Prevention (BIP) Study Group. Am J Cardiol.
1996;77(15):1273–7.
114. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-
blockers for chronic obstructive pulmonary disease. Cochrane
Database Syst Rev. 2005;4:CD003566.
115. Lipworth B, Skinner D, Devereux G, et al. Underuse of b-
blockers in heart failure and chronic obstructive pulmonary
disease. Heart. 2016;102:1909–14.
116. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-
blockers for reversible airway disease. Cochrane Database Syst
Rev. 2002;4:CD002992.
117. Ormiston TM, Salpeter SR. Beta-blocker use in patients with
congestive heart failure and concomitant obstructive airway
disease: moving from myth to evidence-based practice. Heart
Fail Monit. 2003;4(2):45–53.
118. Vestbo J, Hurd SS, Agustı´ AG, et al. Global strategy for the
diagnosis, management, and prevention of chronic obstructive
pulmonary disease: GOLD executive summary. Am J Respir
Crit Care Med. 2013;187:347–65.
119. Global Initiative for Asthma. Global Strategy for Asthma
Management and Prevention; 2016. http://www.ginasthma.org
120. Bhatt SP, Wells JM, Kinney GL, et al. b-Blockers are associated
with a reduction in COPD exacerbations. Thorax.
2016;71(1):8–14.
121. Short PM, Lipworth SIW, Elder DHJ, et al. Effect of b blockers
in treatment of chronic obstructive pulmonary disease: a retro-
spective cohort study. BMJ. 2011;342:d2549.
122. Su VY, Chang Y, Hu Y, et al. Carvedilol, bisoprolol, and
metoprolol use in patients with coexistent heart failure and
chronic obstructive pulmonary disease. Medicine (Baltimore).
2016;95(5):e2427.
123. Kubota Y, Asai K, Furuse E, et al. Impact of b-blocker selec-
tivity on long-term outcomes in congestive heart failure patients
with chronic obstructive pulmonary disease. Int J COPD.
2015;10:515–23.
124. Andell P, Erlinge D, Smith JG, et al. b-Blocker use and mor-
tality in COPD patients after myocardial infarction: a Swedish
nationwide observational study. J Am Heart Assoc.
2015;4:e001611.
125. Coiro S, Girerd N, Rossignol P, et al. Association of beta-
blocker treatment with mortality following myocardial infarc-
tion in patients with chronic obstructive pulmonary disease and
heart failure or left ventricular dysfunction: a propensity mat-
ched-cohort analysis from the High-Risk Myocardial Infarction
Database Initiative. Eur J Heart Fail. 2017;19(2):271–9. doi:10.
1002/ejhf.647.
The Real Role of b-Blockers in Daily Cardiovascular Therapy
